Cover Image
Market Research Report
Product code 
938816

Cell Line Development

Published: | Global Industry Analysts, Inc. | 212 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cell Line Development
Published: April 1, 2021
Global Industry Analysts, Inc.
Content info: 212 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Abstract:

Global Cell Line Development Market to Reach $10.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Cell Line Development estimated at US$4.7 Billion in the year 2020, is projected to reach a revised size of US$10.7 Billion by 2027, growing at a CAGR of 12.3% over the analysis period 2020-2027. Equipment, one of the segments analyzed in the report, is projected to record a 12.5% CAGR and reach US$4.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Reagents & Media segment is readjusted to a revised 12.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 11.8% CAGR

The Cell Line Development market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.9 Billion by the year 2027 trailing a CAGR of 11.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.8% and 10.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9% CAGR.

Accessories & Consumables Segment to Record 6.8% CAGR

In the global Accessories & Consumables segment, USA, Canada, Japan, China and Europe will drive the 6.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$242 Million in the year 2020 will reach a projected size of US$380.6 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.3 Billion by the year 2027.

Select Competitors (Total 44 Featured) -

  • Abzena PLC
  • American Type Culture Collection (ATCC)
  • Apath LLC
  • Bioceros
  • Catalent, Inc.
  • CELLforCURE
  • Cobra Biologics
  • Corning, Inc.
  • Cyagen US Inc.
  • Cytovance Biologics
  • Epistem Holdings PLC
  • EuBiologics Co., Ltd.
  • GE Healthcare
  • GVK Biosciences Private Limited
  • Hitachi Chemical Advanced Therapeutics Solutions, LLC
  • Lonza Group Ltd.
  • MilliporeSigma
  • NAEJA-RGM Pharmaceuticals, Inc.
  • Paragon Bioservices, Inc.
  • Patheon, Inc.
  • Promocell GmbH
  • Samsung BioLogics
  • Sartorius AG
  • Selexis SA
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec
Table of Contents
Product Code: MCP10946

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Cell Line Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
    • TABLE 3: World Current & Future Analysis for Equipment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 4: World 7-Year Perspective for Equipment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 5: World Current & Future Analysis for Reagents & Media by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 6: World 7-Year Perspective for Reagents & Media by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Accessories & Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World 7-Year Perspective for Accessories & Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 9: World Current & Future Analysis for Bioproduction by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 10: World 7-Year Perspective for Bioproduction by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 11: World Current & Future Analysis for Tissue Engineering & Regenerative medicine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 12: World 7-Year Perspective for Tissue Engineering & Regenerative medicine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 13: World Current & Future Analysis for Toxicity Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World 7-Year Perspective for Toxicity Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 15: World Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 16: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 17: World Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 18: World 7-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World 7-Year Perspective for Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 21: World Current & Future Analysis for Non-Mammalian by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 22: World 7-Year Perspective for Non-Mammalian by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 23: World Current & Future Analysis for Recombinant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 24: World 7-Year Perspective for Recombinant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 25: World Current & Future Analysis for Hybridomas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 26: World 7-Year Perspective for Hybridomas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 27: World Current & Future Analysis for Continuous Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 28: World 7-Year Perspective for Continuous Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
    • TABLE 29: World Current & Future Analysis for Primary Cell Line by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 30: World 7-Year Perspective for Primary Cell Line by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 31: USA Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: USA 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 33: USA Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 34: USA 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 35: USA Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 36: USA 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 37: USA Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: USA 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • CANADA
    • TABLE 39: Canada Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 40: Canada 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 41: Canada Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 42: Canada 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 43: Canada Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Canada 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 45: Canada Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 46: Canada 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • JAPAN
    • TABLE 47: Japan Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 48: Japan 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 49: Japan Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: Japan 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 51: Japan Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 52: Japan 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 53: Japan Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 54: Japan 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • CHINA
    • TABLE 55: China Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: China 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 57: China Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 58: China 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 59: China Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 60: China 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 61: China Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 62: China 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • EUROPE
    • TABLE 63: Europe Current & Future Analysis for Cell Line Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 64: Europe 7-Year Perspective for Cell Line Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
    • TABLE 65: Europe Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 66: Europe 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 67: Europe Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 69: Europe Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 70: Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 71: Europe Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 72: Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • FRANCE
    • TABLE 73: France Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: France 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 75: France Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 76: France 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 77: France Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 78: France 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 79: France Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 80: France 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • GERMANY
    • TABLE 81: Germany Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 82: Germany 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 83: Germany Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 84: Germany 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 85: Germany Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Germany 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 87: Germany Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 88: Germany 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • ITALY
    • TABLE 89: Italy Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 90: Italy 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 91: Italy Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Italy 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 93: Italy Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 94: Italy 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 95: Italy Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 96: Italy 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • UNITED KINGDOM
    • TABLE 97: UK Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 98: UK 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 99: UK Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 100: UK 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 101: UK Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 102: UK 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 103: UK Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: UK 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • REST OF EUROPE
    • TABLE 105: Rest of Europe Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 106: Rest of Europe 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 107: Rest of Europe Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 108: Rest of Europe 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 109: Rest of Europe Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Rest of Europe 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 111: Rest of Europe Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 112: Rest of Europe 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 113: Asia-Pacific Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 114: Asia-Pacific 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 115: Asia-Pacific Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Asia-Pacific 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 117: Asia-Pacific Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 118: Asia-Pacific 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 119: Asia-Pacific Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 120: Asia-Pacific 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027
  • REST OF WORLD
    • TABLE 121: Rest of World Current & Future Analysis for Cell Line Development by Product Type - Equipment, Reagents & Media and Accessories & Consumables - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 122: Rest of World 7-Year Perspective for Cell Line Development by Product Type - Percentage Breakdown of Value Sales for Equipment, Reagents & Media and Accessories & Consumables for the Years 2020 & 2027
    • TABLE 123: Rest of World Current & Future Analysis for Cell Line Development by Application - Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 124: Rest of World 7-Year Perspective for Cell Line Development by Application - Percentage Breakdown of Value Sales for Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, Research and Drug Discovery for the Years 2020 & 2027
    • TABLE 125: Rest of World Current & Future Analysis for Cell Line Development by Source - Mammalian and Non-Mammalian - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 126: Rest of World 7-Year Perspective for Cell Line Development by Source - Percentage Breakdown of Value Sales for Mammalian and Non-Mammalian for the Years 2020 & 2027
    • TABLE 127: Rest of World Current & Future Analysis for Cell Line Development by Cell Line - Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 128: Rest of World 7-Year Perspective for Cell Line Development by Cell Line - Percentage Breakdown of Value Sales for Recombinant, Hybridomas, Continuous Cell Line and Primary Cell Line for the Years 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 44